- Home
- FAMI vs ONCO Comparison
FAMI vs ONCO Comparison
Compare FAMI & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FAMI
- ONCO
- Stock Information
- Founded
- FAMI 2015
- ONCO 2018
- Country
- FAMI China
- ONCO United States
- Employees
- FAMI N/A
- ONCO N/A
- Industry
- FAMI Packaged Foods
- ONCO Biotechnology: Pharmaceutical Preparations
- Sector
- FAMI Consumer Staples
- ONCO Health Care
- Exchange
- FAMI Nasdaq
- ONCO Nasdaq
- Market Cap
- FAMI 3.1M
- ONCO 3.6M
- IPO Year
- FAMI 2018
- ONCO 2022
- Fundamental
- Price
- FAMI $0.16
- ONCO $0.13
- Analyst Decision
- FAMI
- ONCO
- Analyst Count
- FAMI 0
- ONCO 0
- Target Price
- FAMI N/A
- ONCO N/A
- AVG Volume (30 Days)
- FAMI 4.4M
- ONCO 2.1M
- Earning Date
- FAMI 03-21-2025
- ONCO 04-10-2025
- Dividend Yield
- FAMI N/A
- ONCO N/A
- EPS Growth
- FAMI N/A
- ONCO N/A
- EPS
- FAMI N/A
- ONCO N/A
- Revenue
- FAMI $64,131,332.00
- ONCO $1,870,605.00
- Revenue This Year
- FAMI N/A
- ONCO N/A
- Revenue Next Year
- FAMI N/A
- ONCO N/A
- P/E Ratio
- FAMI N/A
- ONCO N/A
- Revenue Growth
- FAMI N/A
- ONCO N/A
- 52 Week Low
- FAMI $0.15
- ONCO $0.13
- 52 Week High
- FAMI $0.94
- ONCO $21.40
- Technical
- Relative Strength Index (RSI)
- FAMI 24.69
- ONCO 18.44
- Support Level
- FAMI $0.23
- ONCO $0.16
- Resistance Level
- FAMI $0.29
- ONCO $0.25
- Average True Range (ATR)
- FAMI 0.02
- ONCO 0.03
- MACD
- FAMI -0.01
- ONCO -0.01
- Stochastic Oscillator
- FAMI 9.79
- ONCO 1.56
About FAMI Farmmi Inc.
Farmmi Inc is a supplier of agricultural products. The products of the company are Shiitake Mushroom, Mu Er Mushroom and other edible fungi and other agricultural products. The majority of products are sold in mainland China.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.